A Triplet Drug Combination Against Aggressive Breast Cancer : Oncology Times
An abstract is unavailable.
An abstract is unavailable.
RF infusion on pain intensity and areas of hyperalgesia and allodynia in healthy volunteers. Nine studies were included. The intervention treatment consisted in RF infusion…
The primary end point of overall survival was met in the KEYNOTE-811 trial assessing pembrolizumab in HER2-positive gastrointestinal cancer.
Cytoreductive therapy with rIFNα or hydroxyurea is safe and well tolerated in patients with polycythemia vera under the age of 60 years.
Date: May 22nd (Wednesday) Time: 3 pm Pacific / 6 pm Eastern Where: Online Program GVHD is a potentially life-threatening condition affecting an estimated 50%…
The annual Champions for Change Gala is The Skin Cancer Foundation’s signature fundraising event. Funds raised from the Gala support the Foundation’s lifesaving educational campaigns,…
A monthly newsletter for oncology/hematology fellows, junior faculty and scientists
Krina K. Patel, MD, MSc, discusses her thoughts on moving CAR T-cell therapy up in the lines of treatment for patients with multiple myeloma.
Adding the phosphatidylserine-targeting antibody bavituximab to the immunotherapy agent pembrolizumab may improve response rates without compromising safety in patients with hepatocellular carcinoma, …
Sponsors & Exhibitors, Faculty and Accepted Abstract Authors will receive specific communication regarding registration procedures. Access to Online Platform with recorded scientific sessions (made available…
Major Finding: Nonmalignant BRCA1/BRCA2-mutant breast tissues exhibit markers of immune infiltration and exhaustion. Approach: A single-cell atlas of the human breast maps changes influenced by…